Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Accumulated Expenses (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Accumulated Expenses readings, the most recent being $166.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 628.86% year-over-year to $166.0 million, compared with a TTM value of $166.0 million through Dec 2025, up 628.86%, and an annual FY2025 reading of $166.0 million, up 628.86% over the prior year.
  • Accumulated Expenses hit $166.0 million in Q4 2025 for Apellis Pharmaceuticals, up from $7.1 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $166.0 million in Q4 2025, with the low at $6.7 million in Q3 2024.
  • Median Accumulated Expenses over the past 5 years was $35.2 million (2021), compared with a mean of $57.8 million.
  • The sharpest move saw Accumulated Expenses plummeted 89.28% in 2023, then soared 628.86% in 2025.
  • Year by year, Accumulated Expenses stood at $35.2 million in 2021, then surged by 170.15% to $95.1 million in 2022, then crashed by 89.28% to $10.2 million in 2023, then surged by 123.42% to $22.8 million in 2024, then surged by 628.86% to $166.0 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $166.0 million, $7.1 million, and $139.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.